The National Assembly is discussing legislation with health authorities on health insurance finances for the recovery of drug benefits from pharmaceutical companies, which filed a lawsuit to cancel the disposal of drug price cuts for fraudulent purposes. It is also discussing ways to enhance stability of quality of domestic manufactured medicines by supporting and strengthening GMP regulations.

The National Assembly, the MOHW, and the MFDS are discussing the proposed revision of the Health Insurance Act and the Pharmaceutical Affairs Act. As the National Assembly recently completed the review of the supplementary budget bill and agreed to form a legislative body including the chairman of the Le